ChronoScale Holdings Corporation reported fiscal first quarter 2027 revenue of $41.5 million, a 148% increase from the prior-year period's $16.7 million. The company posted a net loss of $26.4 million and adjusted EBITDA of $5.9 million. Following the business combination completed in May 2026, ChronoScale classified its legacy Ekso Bionics business as held for sale and subsequently completed the sale of that unit on September 30, 2026. The company also secured a 50 MW AI compute deployment with Microsoft and entered strategic partnerships with Nutanix and Baseten Labs. ChronoScale operates an accelerated compute platform purpose-built to support demanding artificial intelligence workloads.
